Sovaldi and Harvoni are not isolated cases. The price of ‘specialty’ drugs–which treat complex chronic conditions such as cancer, HIV or inflammatory disease–has skyrocketed in recent years, fuelling a heated debate about why prices are so high and whether they are justified.
